-
Mashup Score: 20Tumor Characteristics Associated with Preoperatively Detectable ctDNA | GU Oncology Now - 1 month(s) ago
Drs. Ben-David, Joyce share an analysis on recurrence-free survival according to ctDNA status in patients with renal masses.
Source: www.guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 5
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field at the 2025 American Urological Association annual meeting.
Source: www.guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
đź“ş In a new interview with @DrJohnSfakianos of @IcahnMountSinai, Dr. Sfakianos describes the history and use of #ctDNA in the GU oncology field: https://t.co/9LQnvotY0a https://t.co/S5zNhNdnWR
-
-
Mashup Score: 6Transforming Colorectal Cancer Management With... : Oncology Times - 2 month(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine NewsTweet-
With several MRD-guided trials underway exploring the many ways circulating tumor DNA (#ctDNA) can improve patient care, clinicians are keen to learn more how to use this technology to help inform treatment decisions today. https://t.co/pUwb8XdlzY https://t.co/o33abHLDtv
-
-
Mashup Score: 0Machine Learning Transforms Multicancer Detection Tests - 3 month(s) ago
This review discusses the current state of multicancer early detection tests, the role of machine learning in their development, and their implications for oncology practice and patient care.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Multicancer early detection tests revolutionize oncology by using blood samples to detect multiple cancers early. Combining #ctDNA analysis and machine learning, they aim to diagnose cancers at curable stages. https://t.co/K3J8r1oMZE
-
-
Mashup Score: 40
PURPOSEImmunoscore (IS) and circulating tumor DNA (ctDNA) are two emerging technologies in improving prognostication and tailoring adjuvant treatments in patients resected from a stage III colon cancer (CC). Here, we analyzed the prognostic value of the …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Beyond #ctDNA MRD, what else can help stratify these patients? Intriguing that immunoscore within patients who are ctDNA➖ can further delineate groups👇🏽: 2yr DFS 🟢—— 💯% 🔵—— 90% 🔴—— 86% @JCO_ASCO https://t.co/oh6u0GDSbd The IDEA💡🇫🇷 initial ctDNA studies. @OncoAlert https://t.co/eCbmtKxWhw
-
-
Mashup Score: 13High sensitivity ctDNA assays in genitourinary malignancies: current evidence and future directions - 10 month(s) ago
Molecular residual disease (MRD) tests have the potential to revolutionize neoadjuvant and adjuvant treatment. This article reviews current evidence for th
Source: academic.oup.comCategories: General Medicine News, Oncologists1Tweet-
High-sensitivity #ctDNA tests can be used to detect radiologically occult disease or minimal residual disease post-surgery & identify high-risk patients. This review summarizes current evidence, w/ focus on genitourinary tumors. @KartikPatel___ https://t.co/d9TyXX3SmD https://t.co/EvIOQJx0hh
-
-
Mashup Score: 2David Gandara: Jonathan Riess about impact of baseline positive vs negative plasma ctDNA - OncoDaily - 10 month(s) ago
David Gandara: Jonathan Riess about impact of baseline positive vs negative plasma ctDNA / Cal Cancer Consortium, cancer, Cancer research, chemotherapy, ctDNA
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: Jonathan Riess about impact of baseline positive vs negative plasma ctDNA - @drgandara https://t.co/lULxsYGjyU #ctDNA #Can…
-
-
Mashup Score: 5The Next Wave of Cancer Care: ctDNA’s Emerging Role - 11 month(s) ago
As the clinical utility of ctDNA continues to be assessed, it is becoming a valuable tool for various cancer types, including gastrointestinal cancers, blood cancers, and other solid tumors.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
While the clinical utility of #ctDNA continues to be evaluated, it is emerging as a useful tool across various cancer types. Read more in this article which features @ADesaiMD, @pashtoonkasi, @marklewismd, @DrLaCasce! https://t.co/cW4ZPqismS
-
-
Mashup Score: 4
In this feature article, key opinion leaders look at the burgeoning use of ctDNA to dictate treatment approaches for patients with bladder cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
“The presence or absence of #ctDNA after surgery is helping physicians and patients make informed decisions on whether there would actually be a benefit from the cytotoxic chemotherapy or not,” -@alantanmd of @VUMCDiscoveries. https://t.co/ikT0yz52w2
-
-
Mashup Score: 4
During a Case-Based Roundtable® event, Ruth M. O’Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Ruth M. O'Regan, MD, discussed whether to order next-generation sequencing and/or #ctDNA testing for a patient with HR–positive breast cancer after progression. @WilmotCancer https://t.co/PIFIxlUJsj
-
đź“ş @ReubenBenDavid1 of @IcahnMountSinai, and Daniel Joyce, MD, of @VUMCDiscoveries, share the reasoning and findings of an analysis on the pathological and clinical features associated with preoperatively detectable #ctDNA: https://t.co/e2RRJiqox0 https://t.co/4JBOh68VK5